c 1311 has been researched along with camptothecin in 3 studies
Studies (c 1311) | Trials (c 1311) | Recent Studies (post-2010) (c 1311) | Studies (camptothecin) | Trials (camptothecin) | Recent Studies (post-2010) (camptothecin) |
---|---|---|---|---|---|
52 | 1 | 23 | 13,002 | 2,229 | 5,391 |
Protein | Taxonomy | c 1311 (IC50) | camptothecin (IC50) |
---|---|---|---|
Histone deacetylase 3 | Homo sapiens (human) | 0.05 | |
Multidrug resistance-associated protein 4 | Homo sapiens (human) | 7.4 | |
DNA topoisomerase 1 | Homo sapiens (human) | 1.9799 | |
Somatostatin receptor type 1 | Homo sapiens (human) | 0.0022 | |
Somatostatin receptor type 2 | Homo sapiens (human) | 0.0022 | |
Somatostatin receptor type 4 | Homo sapiens (human) | 0.0022 | |
Somatostatin receptor type 3 | Homo sapiens (human) | 0.0022 | |
Somatostatin receptor type 5 | Homo sapiens (human) | 0.0022 | |
5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.97 | |
Histone deacetylase 4 | Homo sapiens (human) | 0.05 | |
Histone deacetylase 1 | Homo sapiens (human) | 0.05 | |
Histone deacetylase 7 | Homo sapiens (human) | 0.05 | |
Histone deacetylase 2 | Homo sapiens (human) | 0.05 | |
Polyamine deacetylase HDAC10 | Homo sapiens (human) | 0.05 | |
Histone deacetylase 11 | Homo sapiens (human) | 0.05 | |
Histone deacetylase 8 | Homo sapiens (human) | 0.05 | |
Histone deacetylase 6 | Homo sapiens (human) | 0.05 | |
Histone deacetylase 9 | Homo sapiens (human) | 0.05 | |
Histone deacetylase 5 | Homo sapiens (human) | 0.05 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (66.67) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Assaraf, YG; Bram, EE; Grimberg, M; Ifergan, I; Lemke, K; Skladanowski, A | 1 |
Alami, N; Belanger, S; Grieshaber, CK; Juste, S; Leyland-Jones, B; Paterson, J | 1 |
Bejrowska, A; Mazerska, Z; Mróz, A; Pawłowska, M | 1 |
3 other study(ies) available for c 1311 and camptothecin
Article | Year |
---|---|
C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells.
Topics: Acridines; Aminoacridines; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Amplification; Gene Expression Regulation, Neoplastic; Heterozygote; Humans; Indoles; Irinotecan; Mitoxantrone; Neoplasm Proteins; RNA, Messenger; Triazoles | 2007 |
Comparative cytotoxicity of C-1311 in colon cancer in vitro and in vivo using the hollow fiber assay.
Topics: Aminoacridines; Animals; Antineoplastic Agents; Camptothecin; Capecitabine; Cell Line, Tumor; Cell Proliferation; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Fluorouracil; HT29 Cells; Humans; In Vitro Techniques; Irinotecan; Mice; Mice, Nude; Organoplatinum Compounds; Oxaliplatin; Paclitaxel | 2007 |
Modulation of UDP-glucuronidation by acridinone antitumor agents C-1305 and C-1311 in HepG2 and HT29 cell lines, despite slight impact in noncellular systems.
Topics: Acridines; Aminoacridines; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Glucuronides; Glucuronosyltransferase; Hep G2 Cells; HT29 Cells; Humans; Irinotecan; Isoenzymes; Microsomes, Liver; Triazoles | 2018 |